Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Psychedelics, placebo effects, and set and setting: Insights from common factors theory of psychotherapy
Natalie Gukasyan, Sandeep M. Nayak
Transcultural Psychiatry (2021) Vol. 59, Iss. 5, pp. 652-664
Closed Access | Times Cited: 101

Showing 1-25 of 101 citing articles:

Blinding and expectancy confounds in psychedelic randomized controlled trials
Suresh Muthukumaraswamy, Anna Forsyth, Thomas Lumley
Expert Review of Clinical Pharmacology (2021) Vol. 14, Iss. 9, pp. 1133-1152
Closed Access | Times Cited: 208
Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials
Jacob S. Aday, Boris D. Heifets, Steven D. Pratscher, et al.
Psychopharmacology (2022) Vol. 239, Iss. 6, pp. 1989-2010
Open Access | Times Cited: 146
Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial
Jordan Sloshower, Patrick D. Skosnik, Hamideh Safi-Aghdam, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 7, pp. 698-706
Closed Access | Times Cited: 84
Treatment with psychedelics is psychotherapy: beyond reductionism
Gerhard Gründer, Manuela Brand, Lea J. Mertens, et al.
The Lancet Psychiatry (2023) Vol. 11, Iss. 3, pp. 231-236
Closed Access | Times Cited: 42
The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder
Adam W. Levin, Rafael Lancelotta, Nathan D. Sepeda, et al.
PLoS ONE (2024) Vol. 19, Iss. 3, pp. e0300501-e0300501
Open Access | Times Cited: 22
Assessing the risk–benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research
David A. Bender, David J. Hellerstein
Psychopharmacology (2022) Vol. 239, Iss. 6, pp. 1907-1932
Closed Access | Times Cited: 64
Expectancy in placebo-controlled trials of psychedelics: if so, so what?
Matthew Butler, Luke A. Jelen, James Rucker
Psychopharmacology (2022) Vol. 239, Iss. 10, pp. 3047-3055
Open Access | Times Cited: 54
Dark loops: contagion effects, consistency and chemosocial matrices in psychedelic-assisted therapy trials
Tehseen Noorani, Gillinder Bedi, Suresh Muthukumaraswamy
Psychological Medicine (2023) Vol. 53, Iss. 13, pp. 5892-5901
Open Access | Times Cited: 25
Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics
Alaina M. Jaster, Javier González‐Maeso
Molecular Psychiatry (2023) Vol. 28, Iss. 9, pp. 3595-3612
Open Access | Times Cited: 22
Preliminary evidence for the importance of therapeutic alliance in MDMA-assisted psychotherapy for posttraumatic stress disorder
Richard J. Zeifman, Hannes Kettner, Stephen Ross, et al.
European journal of psychotraumatology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 14
Exploring mechanisms of psychedelic action using neuroimaging
David Erritzøe, Christopher Timmermann, Kate Godfrey, et al.
Nature Mental Health (2024) Vol. 2, Iss. 2, pp. 141-153
Closed Access | Times Cited: 11
A framework for assessment of adverse events occurring in psychedelic-assisted therapies
Roman Palitsky, Deanna M. Kaplan, John Perna, et al.
Journal of Psychopharmacology (2024) Vol. 38, Iss. 8, pp. 690-700
Closed Access | Times Cited: 11
Giving Consent to the Ineffable
Daniel Villiger
Neuroethics (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 10
Misinterpretations and Omissions: A Critical Response to Goodwin and Colleagues’ Commentary on Psilocybin-Assisted Therapy
Kelley C. O’Donnell, B. Anderson, Frederick S. Barrett, et al.
American Journal of Psychiatry (2024) Vol. 181, Iss. 1, pp. 74-75
Closed Access | Times Cited: 9
Psychedelic-assisted psychotherapy: where is the psychotherapy research?
Jacob S. Aday, David Horton, Gisele Fernandes‐Osterhold, et al.
Psychopharmacology (2024) Vol. 241, Iss. 8, pp. 1517-1526
Closed Access | Times Cited: 9
Psychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research
Roger S. McIntyre, Angela T.H. Kwan, Rodrigo B. Mansur, et al.
American Journal of Psychiatry (2025) Vol. 182, Iss. 1, pp. 21-32
Closed Access | Times Cited: 1
Culture, context, and ethics in the therapeutic use of hallucinogens: Psychedelics as active super-placebos?
David Dupuis, Samuel P. L. Veissière
Transcultural Psychiatry (2022) Vol. 59, Iss. 5, pp. 571-578
Closed Access | Times Cited: 33
Holding on or letting go? Patient experiences of control, context, and care in oral esketamine treatment for treatment-resistant depression: A qualitative study
Joost J. Breeksema, Alistair Niemeijer, Bouwe Kuin, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 30
A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions
Bill Brennan, Alex R. Kelman, Alexander B. Belser
Psychedelic Medicine (2023) Vol. 1, Iss. 4, pp. 218-229
Open Access | Times Cited: 21
Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation
Nadav Liam Modlin, Tammy M. Miller, James Rucker, et al.
Journal of Affective Disorders (2023) Vol. 326, pp. 18-25
Closed Access | Times Cited: 18
With great power comes great vulnerability: an ethical analysis of psychedelics’ therapeutic mechanisms proposed by the REBUS hypothesis
Daniel Villiger, Manuel Trachsel
Journal of Medical Ethics (2023) Vol. 49, Iss. 12, pp. 826-832
Open Access | Times Cited: 16
Longitudinal associations between psychedelic use and psychotic symptoms in the United States and the United Kingdom
Ludwig Honk, Cecilia U. D. Stenfors, Simon B. Goldberg, et al.
Journal of Affective Disorders (2024) Vol. 351, pp. 194-201
Closed Access | Times Cited: 7
How Do Psychedelics Reduce Fear of Death?
Chris Letheby
Neuroethics (2024) Vol. 17, Iss. 2
Open Access | Times Cited: 6
Novel Treatment Approaches for Substance Use Disorders: Therapeutic Use of Psychedelics and the Role of Psychotherapy
Michael Koslowski, Matthew W. Johnson, Gerhard Gründer, et al.
Current Addiction Reports (2021) Vol. 9, Iss. 1, pp. 48-58
Open Access | Times Cited: 32
Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling
Jack E. Henningfield, Marion A. Coe, Roland R. Griffiths, et al.
Neuropharmacology (2022) Vol. 218, pp. 109220-109220
Open Access | Times Cited: 24
Page 1 - Next Page

Scroll to top